Indaptus Therapeutics, Inc. Comprehensive Income
Indaptus Therapeutics, Inc. (INDP) reported Comprehensive Income of -$15.02 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2025-03-13
- Indaptus Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-12-31 was -$4.13M.
- Indaptus Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-09-30 was -$3.07M.
- Indaptus Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-06-30 was -$4.02M.
- Indaptus Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-03-31 was -$3.81M.
- Indaptus Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$15.02M.
- Indaptus Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$15.52M.
- Indaptus Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$14.23M.
- Indaptus Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$7.71M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$7.20M derived: sum of 2 quarters · filed 2025-03-13 | -$11.22M derived: sum of 3 quarters · filed 2025-03-13 | -$15.02M 10-K · filed 2025-03-13 |
| 2024-09-30 | -$3.07M 10-Q · filed 2024-11-12 | -$7.08M derived: sum of 2 quarters · filed 2024-11-12 | -$10.89M 10-Q · filed 2024-11-12 | -$14.89M derived: sum of 4 quarters · filed 2025-03-13 |
| 2024-06-30 | -$4.02M 10-Q · filed 2024-08-12 | -$7.82M 10-Q · filed 2024-08-12 | -$11.82M derived: sum of 3 quarters · filed 2025-03-13 | -$15.88M derived: sum of 4 quarters · filed 2025-03-13 |
| 2024-03-31 | -$3.81M 10-Q · filed 2024-05-08 | -$7.81M derived: sum of 2 quarters · filed 2025-03-13 | -$11.87M derived: sum of 3 quarters · filed 2025-03-13 | -$15.15M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-12-31 | -$4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$8.06M derived: sum of 2 quarters · filed 2025-03-13 | -$11.35M derived: sum of 3 quarters · filed 2025-03-13 | -$15.52M 10-K · filed 2025-03-13 |
| 2023-09-30 | -$4.06M 10-Q · filed 2024-11-12 | -$7.34M derived: sum of 2 quarters · filed 2024-11-12 | -$11.52M 10-Q · filed 2024-11-12 | -$15.09M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$3.29M 10-Q · filed 2024-08-12 | -$7.46M 10-Q · filed 2024-08-12 | -$11.04M derived: sum of 3 quarters · filed 2024-08-12 | -$14.46M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$4.17M 10-Q · filed 2024-05-08 | -$7.75M derived: sum of 2 quarters · filed 2024-05-08 | -$11.17M derived: sum of 3 quarters · filed 2024-05-08 | -$15.02M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$7.00M derived: sum of 2 quarters · filed 2024-03-13 | -$10.85M derived: sum of 3 quarters · filed 2024-03-13 | -$14.23M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$3.42M 10-Q · filed 2023-11-06 | -$7.28M derived: sum of 2 quarters · filed 2023-11-06 | -$10.65M 10-Q · filed 2023-11-06 | -$13.87M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$3.85M 10-Q · filed 2023-08-14 | -$7.23M 10-Q · filed 2023-08-14 | -$10.44M derived: sum of 3 quarters · filed 2023-08-14 | -$13.81M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$3.37M 10-Q · filed 2023-05-11 | -$6.59M derived: sum of 2 quarters · filed 2023-05-11 | -$9.96M derived: sum of 3 quarters · filed 2023-05-11 | -$10.47M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$6.58M derived: sum of 2 quarters · filed 2023-03-17 | -$7.10M derived: sum of 3 quarters · filed 2023-03-17 | -$7.71M 10-K · filed 2023-03-17 |
| 2021-09-30 | -$3.37M 10-Q · filed 2022-11-10 | -$3.88M derived: sum of 2 quarters · filed 2022-11-10 | -$4.50M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$515.48K 10-Q · filed 2022-08-08 | -$1.13M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | -$612.42K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |